A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

NCT06460324 · clinicaltrials.gov ↗
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Novartis Pharmaceuticals